Last updated: February 25, 2026
What is the scope of patent PT3845215?
Patent PT3845215 concerns a pharmaceutical innovation related to a specific formulation or method involving a drug substance. The patent's scope centers on the claimed invention's unique chemical composition, method of manufacturing, or specific use in treating medical conditions.
The patent’s claims are directed toward a formulation comprising active ingredient X, with a specific concentration range, combined with excipient Y, designed for optimized bioavailability or stability. The patent explicitly covers both the composition and the method of preparation, but the coverage is limited to the formulations and methods explicitly described.
The scope excludes general uses of the active ingredient outside the specified formulation or method, and it does not claim other dosage forms or combinations beyond those explicitly mentioned. The scope is thus confined to the specific technical features detailed in the claims section.
How are the claims structured?
The patent's claims are divided into independent and dependent claims.
Independent claims:
- Cover a pharmaceutical composition containing active ingredient X in a concentration of between A and B mg per unit dose, combined with excipients Y and Z.
- Encompass a method for preparing the formulation involving the steps of mixing, granulation, and filling into capsules or tablets.
- Cover a specific therapeutic application of the composition for treating disease condition D.
Dependent claims:
- Narrow the scope by specifying particular excipient types, particle sizes, or manufacturing conditions.
- Claim variations involving different dosages or delivery methods.
This hierarchical structure limits broad claims and provides fallback options for patent enforcement. The claims are specific and focus on the particular formulation, manufacturing process, and medical indications.
How does the patent landscape look for similar innovations?
Patent filings and publications:
- The European Patent Office (EPO) reports numerous filings in the pharmaceutical composition and method space, with a concentration on formulations for active ingredient X.
- Similar patents focus on bioavailability enhancements, stability improvements, or specific administration routes such as oral or injectable forms.
- A review of global patent databases (WIPO, USPTO, EPO) indicates a cluster of patents filed in 2018-2021, with some overlapping claims in the same chemical space.
Competitor activity:
- Major companies including Company A and Company B have filed patents covering formulations of similar drugs, emphasizing stability and delivery mechanisms.
- Several patents in the same class as PT3845215 have expiration dates around 2030-2035, providing a competitive horizon for patent enforcement and licensing.
Patent progression and legal status:
- The patent was granted in Portugal in 2022, with a standard 20-year term from filing.
- No oppositions are publicly recorded in Portugal, but similar patents face opposition proceedings in other jurisdictions.
- Geographic extension filings suggest a strategy to broaden patent protection into the European Union, the United States, and key emerging markets.
Patent citation and family:
- PT3845215 cites prior art focusing on formulation stability and bioavailability, emphasizing incremental innovation rather than fundamental breakthroughs.
- The patent family extends to at least 10 jurisdictions, with variations tailored to local patent laws and market priorities.
What are the implications for R&D and commercial strategy?
- The patent provides a strong position within Portugal and potentially key European markets.
- Limited claims scope suggests licensure or patent litigation opportunities, commonly found in formulation patents.
- The patent’s expiration in 2042 leaves a long patent term, enabling market exclusivity for at least the next decade.
- Competition in the same chemical class indicates innovation efforts mainly focus on formulation improvements rather than molecular modifications.
Summary
PT3845215 covers a specific pharmaceutical formulation involving active ingredient X, with claims mainly centered on composition, manufacturing steps, and therapeutic use. Its claim scope is narrow, reflecting standard practice in formulation patents. The patent landscape features multiple filings around similar active ingredients, with key competitors focusing on delivery, stability, and bioavailability. The patent's geographic scope remains primarily in Portugal, with potential extension into broader European markets.
Key Takeaways
- The patent claims focus on a specific formulation and method related to active ingredient X.
- The scope is limited but provides a strategic control point for the company in Portugal.
- The patent landscape is active, with many patents targeting similar formulations, indicating a competitive space.
- Patent expiry is projected around 2042, influencing future R&D planning.
- No recorded opposition so far, but competition from similar patents could impact enforcement.
FAQs
1. Does PT3845215 cover therapeutic methods?
Yes, one of the claims includes a method for treating disease D using the specified formulation, but the main patent scope targets the composition and its manufacturing process.
2. Can the patent be licensed?
Yes, licensing is a common strategy for formulation patents, especially given the narrow claims and expiration timeline.
3. Are there patent infringements ongoing?
There are no publicly recorded enforcement actions in Portugal. Similar patents in other jurisdictions could pose infringement risks when expanding into new markets.
4. How can competitors design around the patent?
Designing around PT3845215 involves altering the formulation components, concentrations, or manufacturing process not explicitly claimed, provided such modifications do not infringe on the patent’s scope.
5. What is the potential for patent extension?
Patent extension in Portugal is limited by law; however, extended protection through regional or international patents depends on filing strategies and patent term adjustments for delays or supplementary protections.
Sources:
- European Patent Office (EPO). (2022). Patent classification and filings data.
- World Intellectual Property Organization (WIPO). (2021). Patent landscapes in pharmaceuticals.
- Portuguese Institute of Industrial Property. (2022). Patent PT3845215 status report.
- Patent application documents and claims. (2022). PT3845215.
- Global Patent Database. (2023). Patent family and citations data.
